Clinician-provided abortions in the United States held remarkably steady last year, even as more states locked in total or near-total bans. Federal data and accounts from providers suggest that the flat national numbers have less to do with stability on the ground and more to do with a rapid pivot to medication abortion delivered by telemedicine and mail, a workaround that has quietly become central to access in many restricted states, as reported by NPR.
According to NPR, which reviewed new figures, the Guttmacher Institute estimates there were roughly 1.1 million clinician-provided abortions in 2025, about the same total as the year before. NPR reports that medication-by-mail and telehealth networks supplied a sizable share of abortions for people living in states with bans, softening what might otherwise have been a sharp national drop.
Telemedicine Is Replacing Travel For Many Patients
Guttmacher’s Monthly Abortion Provision Study found an estimated 518,940 clinician-provided abortions in the first half of 2025 in states without total bans, and it documents a decline in out-of-state travel for care as telemedicine stepped in to cover some of the need, according to the Guttmacher Institute. The institute also notes that online and virtual-only clinics have taken on a growing role even as the number of brick-and-mortar clinics dipped slightly between 2024 and 2025.
Mail Orders And Shield Laws Keep Care Flowing
NPR reported that about 91,000 patients in states with abortion bans received and used mifepristone and misoprostol through telehealth in 2025, with patients describing mailed medication accompanied by clear instructions and available follow-up. Providers who ship the pills say their protocols rely on screening and check-ins to confirm that the regimen worked and to address complications, which they argue keeps the model both safe and accessible for people who cannot travel.
Courts Could Upend The Mail-Order Pipeline
The legal footing for that system is far from settled. Coverage of a Feb. 24 hearing in Louisiana v. FDA describes how the state pressed a federal judge to reinstate an in-person dispensing requirement and requested a preliminary injunction, according to OSV News. That challenge zeroes in on a January 2023 FDA modification of the mifepristone REMS that removed the long-standing in-person pickup rule and opened the door for certified pharmacies and telehealth prescribing in many jurisdictions, according to the FDA.
Shield Laws And State Protections
A patchwork of shield laws in roughly 22 states and the District of Columbia has helped insulate some patients and out-of-state prescribers by limiting cooperation with outside investigations and, in several jurisdictions, extending those protections to telehealth, according to Guttmacher. At the same time, other states and federal lawsuits are moving in the opposite direction, seeking to block mailed pills or penalize cross-state prescribing, which has introduced sudden legal and operational hazards for the very telehealth networks that have kept overall access from collapsing.
The practical takeaway is blunt: state bans have shifted where abortions are happening, but not necessarily how many occur. With courts weighing challenges to the FDA rules and lawmakers pushing conflicting bills, access will hinge on a fast-changing mix of policy choices, provider strategies and the resilience of the telemedicine systems that have rushed in to fill the gaps.
